Lobbying Information
Subject Matters
- Consumer Issues
- Government Procurement
- Health
- Industry
- Intellectual Property
- International Relations
- International Trade
- Regional Development
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- National Immunization Strategy. Advocacy to seek continued funding in vaccines.
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Health Canada's Consultation on fee proposal for drugs and medical devices
- The international trade negotiations under the North American Free Trade Agreement as it relates to potential legislative or regulatory changes of Canada's intellectual property regime for pharmaceutical products (Patent Act); Regulatory harmonization; the outdated supply chain regulations; pricing; cross-border trade; and confidential business information.
Legislative Proposal, Bill or Resolution, Regulation
- Patent Act as it relates to the implementation of the Comprehensive Economic Trade Agreement (CETA) and its Intellectual property protection provisions.
Policies or Program
- Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
- Patented Medicine Prices Review Board (PMPRB)consultation on the proposed modernization of the Compendium of Policies, Guidelines and Procedures
- The Department of Innovation, Science and Economic Development consultation on the new Innovation Agenda: policy or program initiatives to support life science Research and Development conducted in Canada
Policies or Program, Regulation
- Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpuse of obtaining a notice of compliance.
- Subsequent Entry Biologics (SEBs) and Orphan Drugs framework: seeking an approval framework supported and protected by Regulations in harmonization with other developed countries
Regulation
- Health Canada's consultation on the future of Regulation of Self-Care Products
- Proposed modernization of the Patented Medicines Prices Review Board (PMPRB) Regulations in the consultation document “Protecting Canadians from Excessive Drug Prices”
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Atlantic Canada Opportunities Agency (ACOA)
-
Canada Economic Development for Quebec Regions
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Employment and Social Development Canada (ESDC)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Indigenous and Northern Affairs Canada
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
National Defence (DND)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
-
Western Economic Diversification Canada (WD)
In-house Corporation Details
Description of activities
Pfizer's mission is to discover and develop innovative medicines, vaccines and other products to improve the quality of life of people and animals.
Responsible officer name and position during the period of this registration
John Helou,
Président et chef de la direction
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC H9J 2M5
Canada
Telephone number:
514-693-4563
Fax number:
514-426-6921
Parent Company Information
- PFIZER INC
-
235 EAST 42ND STREET
NEW YORK, NY 10017-5755
United States of America
Subsidiary Beneficiary Information
Pfizer Canada ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Jonathan Cullen,
Vice-President, Legal Affairs & General Counsel |
No public offices held
- John Helou,
Président et chef de la direction |
No public offices held
- Frédéric Lavoie,
Vice-président, Remboursement et relations gouvernementales |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
